News & Updates
Excerpt from the Press Release: MADRID and CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the European Medicines Agency (EMA) has authorized its Clinical Trial Application (CTA) to initiate a Phase II study of…
– Trial met primary efficacy endpoint at week 12 – EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo – 33% placebo-adjusted improvement in EASI at week 12 – 23% of EVO301 patients achieved IGA 0/1 at week 12 Excerpt from the Press Release: PALO ALTO, Calif. & NEW…
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31, 2026 of approximately $9 million anticipated to extend cash runway through Q4 2026 Excerpt from the Press Release: SAN FRANCISCO, CALIFORNIA, Feb. 03, 2026…
Multiple patients substantially exceed expected survival at low dose levels; absence of dose-limiting toxicities supports escalation to doses up to 100x higher Trial expansion reflects growing confidence in intra-peritoneal CAR-T delivery and introduceslymphodepletion to potentially enhance efficacy Anixa to participate in Water Tower Research fireside chat at 11:00am ET on February 10, 2026to discuss trial…
Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platform Excerpt from the Press Release: SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) — Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the first patient has been dosed in the Phase 1/2 clinical trial (NCT07300241)…
Excerpt from the Press Release: BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) — Curium Group today announced that together with PeptiDream Inc. and PDRadiopharma Inc., the first patient has been dosed in the companies’ registrational clinical trial of 177Lu-PSMA-I&T in Japan for patients with PSMA (*1)-positive metastatic castration-resistant prostate cancer (mCRPC). 177Lu-PSMA-I&T is a radiotherapeutic agent…
Excerpt from the Press Release: WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) — Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that it has completed enrollment in the Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary…
KTX-2001 being evaluated both as a monotherapy and in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC) Shinta Cheng, M.D., Ph.D., joins company as Chief Medical Officer Excerpt from the Press Release: CAMBRIDGE, Mass., Feb. 5, 2026 /PRNewswire/ — K36 Therapeutics, Inc. (“K36”), a privately held clinical-stage biotechnology company developing novel targeted therapies for…
AFTX-201 uses Affinia’s proprietary capsid engineered for efficient cardiac transduction at doses that are 5-10-fold lower than doses of gene therapies using conventional capsids Company on track to initiate the UPBEAT© clinical trial to investigate safety, pharmacodynamics, and preliminary efficacy of AFTX-201 in BAG3 DCM in the first half of 2026 Excerpt from the Press Release:…
Initiative will create one of the world’s largest multimodal cancer datasets and an integrated suite of AI models and tools to fuel precision medicine Excerpt from the Press Release: PLEASANTON, Calif., Feb. 4, 2026 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that PharosAI, a research consortium…
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?